131
Views
30
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLEImaging, Diagnosis, Prognosis

Positive Correlation of Osteopontin, Cyclooxygenase-2 and Vascular Endothelial Growth Factor in Gastric Cancer

, , , , , , , , , , , & show all
Pages 60-67 | Published online: 11 Jun 2009
 

Abstract

Osteopontin (OPN), cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) are overexpressed in various experimental models of malignancy. However, the correlation and role of the three molecules in gastric cancer is unclear. In the present study, we found that OPN, COX-2 and VEGF were overexpressed in 53 cancerous tissues with gastric cancer compared with 40 normal mucosa tissues by immunohistochemistry method. Moreover, the results indicated co-expression of OPN, COX-2, and VEGF in gastric cancer. Levels of OPN, COX-2, and VEGF were all significantly correlated with TNM stage, lymph node metastasis and distant metastasis (P < 0.05), while not related to prognosis of patients. In addition, individual levels of OPN, COX-2, and VEGF were all significantly correlated with microvessel density (MVD), valued by CD34 staining directly with r-values of 0.416, 0.400, and 0.566, respectively (P < 0.01). Both OPN and COX-2 levels showed a positive correlation with VEGF (P < 0.05). Meanwhile, expression of COX-2 is in relation to OPN (P < 0.01). Overall, survival for patients with high MVD was significantly lower than for patients with low MVD (P < 0.05). Our findings indicate that OPN, COX-2, and VEGF synergically promote angiogenesis and metastasis in gastric cancer. It may be an important and useful strategy to target these molecules for prevention and therapy of tumor.

ABBREVIATIONS
COX-2,=

cyclooxygenase-2

MVD,=

mean microvessel density

NO,=

nitric oxide

OPN,=

Osteopontin

VEGF,=

vascular endothelial growth factor

ABBREVIATIONS
COX-2,=

cyclooxygenase-2

MVD,=

mean microvessel density

NO,=

nitric oxide

OPN,=

Osteopontin

VEGF,=

vascular endothelial growth factor

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.